The trial, to be performed in Australia, will sign up 640 wholesome adults between the ages of 50 and 70 years and who’ve both been formerly inflamed with the coronavirus or given a licensed COVID-19 vaccine at least eight weeks prior to the take a look at.
members will acquire a combination of the employer’s COVID-19 vaccine candidate, NVX-CoV2373, and its Influenza shot NanoFlu along with an adjuvant or vaccine booster.
“combination of those vaccines…can also result in extra efficiencies for the healthcare machine and obtain excessive levels of protection towards COVID-19 and influenza with a single routine,” Gregory Glenn, President of research and development at Novavax, said in a announcement.
Novavax had stated in can also it expects seasonal influenza and COVID-19 aggregate vaccines to probable be important in preventing emerging COVID-19 versions. Its vaccine NanoFlu/NVX-CoV2373 had elicited sturdy responses to each influenza A and B and protected towards the coronavirus in pre-medical studies.
Novavax expects the trial results in the first half of 2022.
Novavax | Don’t forget to follow us on Twitter @njtimesofficial. To get the latest updates